To assess the impact of dementia on evidence-based medication use after admission for patients with acute coronary syndrome (ACS) across different age groups. METHODS: Of 87,298 patients hospitalized for ACS between January 1, 2006 and December 31, 2007, 1835 patients with dementia and 3670 matched patients without dementia (1:2 ratio, matched by age, gender, and admitted hospital level) were identified from Taiwan's National Health Insurance Research Database. Use of evidence-based medications post-discharge were compared between patients with and without dementia across different age groups (Յ65, 66-75, 76-85, Ͼ85). Multivariate logistic regression models were performed to examine the impact of dementia on use of evidence-based medications. RESULTS: Overall, dementia was associated with a 22% lower likelihood of use of evidence-based medications (adjusted odds ratio (OR) ϭ 0.78, CIϭ0.68-0.89) in ACS patients. The use of evidence-based medications decreased with age, and dementia worsened the utilization. The proportions of patients receiving evidence-based medications were 85.6% (without dementia) versus 73.6% (with dementia) in the youngest age group and 62.0 % (without dementia) versus 55.6% (with dementia) in the oldest age group. CONCLUSIONS: Dementia and aging were associated with the use of evidence-based medications in ACS patients. 
OBJECTIVES:
To characterize the real-world profile of hypertension patients in Japan and their treatments, BP control, and health care resource consumption with a primary focus on isolated systolic hypertension (ISH) and the elderly patient population. METHODS: Data were extracted from insurance claims and from annual health examination. Only subjects who had blood pressure readings from their annual health examinations in 2009 and 2010 at 10-14 months apart were included. Subjects were identified by ICD-10-CM. Treatments were evaluated to understand the current distributions with a focus on 65ϩ versus Ͻ65 years of age. Control rates were calculated and costs evaluated by hypertension type. RESULTS: A total of 9269 subjects were identified with a hypertension diagnosis and annual health exam blood pressure readings. Subjects mean age was 51.61(9.54) years old, 72.6% were male, and were diagnosed for 3.72(3.95) years. 56.24% were currently controlled and 15.48% had ISH. Poly-pharmacy for hypertension was common (42.49%). ARBs (47.68%) and CCBs (28.26%) were used most frequently. The number of treatments subjects received increased with the number of years diagnosed, with an average of 1.23 medications within the first year and 2.45 after 10 years. For subjects controlled at baseline, 21.6% reverted to "uncontrolled" 1-year later and 47.9% ISH subjects improved "to-goal". The average cost of treating subjects significantly differed over one year: JPY231,626.32 for "controlled" subjects, JPY230,989.37 for ISH and isolated diastolic subjects were least expensive at JPY141,739.55. Elderly had a significantly higher cost than subjects less than 771.28 vs JPY213, 091.42) . CONCLUSIONS: Hypertension in Japan is characterized by poly-pharmacy and only moderate control. Elderly patients are significantly more costly to treat and "controlled" and ISH patients were the most costly to treat. Treatment was dominated by ARBs and CCBs (alone or in combination with other treatments). 
CV4 ASSOCIATION BETWEEN KNOWLEDGE AND HEALTH RELATED QUALITY OF LIFE? IS PATIENT EDUCATION ALWAYS BENEFICIAL?

OBJECTIVES:
To evaluate association between HRQoL and knowledge among hypertensive population of Pakistan. METHODS: A cross sectional descriptive study was undertaken with a representative cohort of hypertension patients. Using prevalence based sampling technique, a total of 385 hypertensive patients were selected from two public hospitals of Quetta city, Pakistan. Hypertension Fact Questionnaire (HFQ) and European Quality of Life scale (EQ-5D) were used for data collection. SPSS v 16.0 was used to compute descriptive analysis of patients' demographic and disease related information. Categorical variables were described as percentages while continuous variables were expressed as mean Ϯ standard deviation (SD). Spearman's rho co-relation was used to identify the association between study variables. RESULTS: The mean (ϮSD) age of the patients was 39.02 Ϯ (6.59), with 68.8% males (nϭ265). The mean (ϮSD) duration of hypertension was 3.01Ϯ0.93 years. Forty percent (nϭ154) had bachelor degree with 34.8% (nϭ134) working in private sector. Almost forty one percent (nϭ140) had monthly income of more than 15000 Pakistan rupees (Pk Rs) per month (1 Pk Rsϭ0.01172 US$) with 75.1% (nϭ289) having urban residency. The mean EQ-5D descriptive score (0.46Ϯ0.28) and EQ-VAS score (63.97Ϯ6.62) indicated lower HRQoL in our study participants. Mean knowledge score was 8.03 Ϯ 0.42. Correlation coefficient between HRQoL and knowledge was 0.208 (pϽ 0.001), indicating a week positive association. CONCLUSIONS: Results of this study highlight hypertension knowledge to be weakly associated with HRQoL suggesting that imparting knowledge to patients do not necessarily improve HRQoL. More attention should be given to identify individualized factors affecting HRQoL. 
PODIUM SESSION II: HEALTH CARE EXPENDITURES STUDIES
EX1 THE EFFECTS OF POLYPHARMACY ON HEALTH CARE COSTS AND HOSPITAL ADMISSIONS IN THAI ELDERLY POPULATION: MULTIVARIATE TWO-PART MODELS
OBJECTIVES:
Polypharmacy is a widely known risk factor for adverse drug reactions, drug-drug interactions, and low adherence in the elderly population. There remains a paucity of evidence demonstrating its effect on hospital admissions and costs. This study aims to determine the effects of polypharmacy on hospital admissions and hospital costs among older patients in Thailand. METHODS: A retrospective cohort study was conducted using an electronic patient database in a provincial hospital of Thailand . All patients aged 60 years or older with at least 2 visits during 2009 were included. Exposure of interest is polypharmacy and excessive polypharmacy which were defined as dispensed medications for more than five and ten items, respectively. Outcomes of interest are hospital admissions and hospitalization costs incurred after index date of polypharmacy. We performed two-part model and used poisson regression and log-transformed linear regression with Duan's smearing estimator to determine the effects of polypharmacy on hospital admissions rate and hospitalization costs, respectively. All analyses were adjusted for potential confounders and propensity score. RESULTS: A total of 17,787 elderly patients were included. The mean age was 71 years with 57% female. Forty-two and 12 percent of patients received polypharmacy and excessive polypharmacy, respectively. Excessive polypharmacy was significantly associated with increased risk of admission (adjusted incidence rate ratio (IRR): 3.2 (95% CI; 1.1-5.4)) while only increased trend of admission was found among polypharmacy (IRR: 1.5 (95% CI; 0.9-2.1), Hospitalization costs were significantly higher at $135 (95% CI; 111.0 -159.0) and $25.0 (95% CI; 16.1 -38.0) for excessive polypharmacy and polypharmacy, compared with non-polypharmacy. CONCLUSIONS: Both polypharmacy and excessive polypharmacy have significantly elevated health care costs but only excessive polypharmacy is significantly associated with increased risk of hospital admission. These findings demonstrated the detrimental effects of polypharmacy and highlighted the importance of finding measures to reduce polypharmacy.
EX2 AN OBSERVATION ON THE TREND OF OUTPATIENT CLINIC UTILIZATION AND NUMBERS OF MEDICAL PRESCRIPTION GIVEN IN TAIWAN ELDERLY BETWEEN 1997 AND 2010
Hung YN There are approximately 25.68 million individuals in this registry. The study subjects were the elderly over 65 years old in each year. We had reviewed the prevalence of outpatient clinic visit during the year, average outpatient clinic visit per year, medicine prescription in outpatient clinic of our study subjects. (grouped as numbers of item prescribed; zero, one to four, five to nine and above ten items). RESULTS: The total numbers of study subjects in each year increase from 52,672 in 1997 to 108,444 in 2010. Most of the elderly had utilized outpatient clinic, and the percentage of clinic utilization during these years had been in a rise every year. (93.4% in 1997 versus 96.8% in 2010). For those who had utilized at least one time outpatient clinic resources, the average outpatient visit numbers in this study ranges from 25.6 to 31.3 times/person-year during the period. However, numbers of prescription in each visit had decreased gradually. In 1997, the percentages of no items prescribed, 1-4 items, 5-9 items and more than 10 items prescribed were 50.1%, 28.39%, 20.07% and 1.42% respectively. In 2010, however, the percentages were 53.4%, 33.54%, 12.3% and 0.79% respectively. CONCLUSIONS: The prescription numbers had decreased gradually in the study period. The utilization percentage of outpatient clinic, however, was on a rise. In addition, multiple prescriptions (more than 5 items) was quiet common in our study, medical care givers should pay more attention on the issue of multiple prescription of our elderly. health policy issues. The effects of each policy category were disentangled into Price, Volume and Quality; and where an effect was identifiable, by comparing to the intent of the policy, it was qualified by 3 sets of parameters: Direct-or-Indirect Effect, Desired-or-Undesired Effect and Decreasing-or-Increasing Effect. RESULTS: The identified 10 policies were grouped into 5 main categories: Essential Drug Listing & Price Control (3), Essential Drug Usage Promotion (2), Reimbursed Drug Listing & Price Control (2), Hospital Drug Price Controls (2), and Prescribing-Dispensing Separation (1). The majority (4/5) of the policy categories were targeted directly at lowering drug prices, and did achieve certain Direct-Desired-Decreasing effects on Price. Three of these four policy categories, however, also had indirectundesired effects, mainly manifested as encouraging over-prescribing or lowering drug quality. The other policy aimed at promoting rational pharmaceutical prescribing failed to make tangible impact at national level. CONCLUSIONS: The drug policies implemented during 2009-2011 achieved limited success and new approaches towards reform will be needed to obtain better results. 
EX4 RECENT TRENDS IN COMMUNITY PHARMACY PAYMENT OF NATIONAL HEALTH INSURANCE IN SOUTH KOREA
OBJECTIVES:
To investigate recent trends in reimbursement payment for pharmacy service and pharmaceuticals from the Korean National Health Insurance (NHI) using the NHI claims database. METHODS: Pharmacy claims data were extracted from the Korean NHI database from January 1, 2008 to March 31, 2011 by quarterly unit. The monthly number of prescriptions of each pharmacy, the average number of supply-days per prescription, and payment amount to each pharmacy including cost of pharmaceuticals and dispensing fees were calculated from the claims. The information of all community pharmacies such as the number of pharmacists in practice and pharmacy location was collected. The trends and variation in the pharmacy payment amount and the composition were traced on quarterly basis. RESULTS: Total claims of 15,996 pharmacies were included for analysis. The monthly reimbursed payment per pharmacy increased from 29. 
CONCLUSIONS:
While the number of prescriptions per pharmacist and supplydays of prescriptions were relatively stable, the reimbursement amount per pharmacy showed an increasing trend. The main source of the increase seemed to be the payment for pharmaceuticals rather than pharmacy services. 
PODIUM SESSION II: HEALTH TECHNOLOGY ASSESSMENT STUDIES HT2 COST-EFFECTIVENESS ANALYSIS OF BONE MINERAL DENSITY SCREENING TOOLS
OBJECTIVES:
The aim of this study was to compare the cost effectiveness of BMD-(Bone Mineral Density) screening tools-RA, QUS, pDXA, QCT, and DXA, for women's lifetime bone densitometry exam at 66 years old. METHODS: A total of 101 subjects aged in 60s' were recruited to estimate sensitivity and specificity of each BMD screening tool. A Markov model was developed to analyze the cost-effectiveness of DXA, QUS, RA, pDXA, and QCT. A cohort of 10,000 women aged 66 was constructed for each bone densitometry and a cohort of 10,000 women aged 66 was also constructed as a non-exam group. In the Markov model of osteoporosis and its related fractures, costs and effectiveness measured by QALY were estimated until the cohorts reached 100 years old or died. It was assumed that only costs were discounted by 5% and the compliance for osteoporosis drugs was 38%. Sensitivity analysis was performed on the discount rate and the compliance to osteoporosis drugs. RESULTS: ICER (incremental cost-effectiveness ratio) is an indicator of how much extra costs are needed to increase an extra 1 QALY compared to the reference group. The magnitudes of ICER's were ordered as DXAϽpDXAϽ(QCT, RA, QUS). DXA and pDXA cost extra 398,618 won and 453,947 won, respectively, in order to increase 1 extra QALY compared to the non-exam group, which meant that DXA and pDXA were very cost-effective. The extra costs for QUS, RA, and QCT to increase 1 QALY compared to the non-exam group ranged 530,000 won'590,000 won, which meant that these were also cost-effective. CONCLUSIONS: All the BMD screening tools that were examined in this study were found to be cost-effective in terms of ICER. When the relative cost-effectiveness of pDXA, QUS, RA, and QCT compared with DXA, DXA was predominant over the other. 
HT3 DEVELOPMENT OF A CHECK LIST FOR QUALITY ASSESSMENT OF PHARMACOECONOMIC EVALUATIONS SUBMITTED FOR REIMBURSEMENT IN TAIWAN
OBJECTIVES:
It is not mandatory for pharmaceutical manufacturers to submit cost-effectiveness evidence yet in Taiwan, but an incentive of a maximum 10% mark-up for conducting local cost-effectiveness analysis has been announced since 2010. HTA/CDE (Division of Health Technology Assessment, Center for Drug Evaluation) assists the assessment on the strength of evidence of local cost-effectiveness evaluation, and a checklist was therefore developed to ensure the consistency and to improve the transparency. This study presents the impact of local pharmacoeconomic incentive and the development of the checklist. METHODS: By reviewing other international checklists for quality assessment of pharmacoeconomic evidence and adding items for local adaptation and transferability, a checklist consisting of four dimensions including PICOS, cost-effectiveness analysis design, source of parameters, and overall quality was developed with a four-levelgrading for evidence strength. The local pharmacoeconomic evidence was identified from the dossiers submitted by the manufacturers during 2008-2011, and was independently assessed by the four reviewers in the economic evaluation team of HTA/CDE as reference cases. Discrepancies between reviewers were discussed until consensus was reached. RESULTS: There were 83 and 67 dossiers submitted for reimbursement before and after the incentive was announced, respectively. However, no local pharmacoeconomic evidence has been submitted until eight months after the incentive was announceed. Another four dossiers consist of five local pharmacoeconomic evaluation (one with multiple indications) were submitted in 2011. The strengths of evidence were graded as strong, medium, low, and very low for 0, 1, 2, and 3 cases according to the checklist. CONCLUSIONS: A pragmatic strategy was used to incorporate cost-effectiveness evidence into the drug reimbursement decisions in Taiwan. Local pharmacoeconomic evidence submissions increase slowly after the incentive was announced. A quality assessment checklist was proposed. Further experience will be cumulated and discussed among the submitting bodies, the appraisal committee members, and HTA/CDE. The analysis revealed the initiated collaboration between HTA stakeholders in the Asia region. In the centre of the Asian HTA ecosystem are located the most established agencies in Korea, Taiwan and Thailand where HTA already yields important evidence to inform policy and practice. The visual analysis revealed patterns of collaboration where agencies were 1) referring to each other; 2) referring to the same sources and academic institutions, and 3) absorbing the experience from well-established European HTA agencies such as NICE or IQWIG. CONCLUSIONS: HTA has expanded globally and can be characterised by common patterns in interactions when looking at and refining the evidence required for the reimbursment. Rapidly growing in number and in influence HTA organizations in Asia are strengthening their abilities through collaboration with each other, by involving independent research institutions into the HTA process and by building upon European HTA experience. 
HT4 HEALTH TECHNOLOGY ASSESSMENT MAP IN ASIA -REGIONAL VERSUS INTERNATIONAL INFLUENCES
PODIUM SESSION II: PREFERENCE-BASED OUTCOMES STUDIES
PR1 DOES MEDICATION ADHERENCE CORRELATE WITH HEALTH-RELATED QUALITY OF LIFE? FINDINGS FROM A DESCRIPTIVE ANALYSIS
